Abstract | BACKGROUND: OBJECTIVE: In this review, we summarize data comparing the safety and efficacy of the two monoclonal antibodies in prevention of RSV infection. Other therapeutic options also are discussed. METHODS: RESULTS/CONCLUSION: In a large comparative clinical trial for which peer review is pending, motavizumab proved noninferior to palivizumab for prevention of RSV-related hospital admission in infants with underlying conditions placing them at high risk for hospitalization after RSV infection. In this trial, motavizumab in comparison to palivizumab significantly reduced the severity of illness among those infants hospitalized with RSV infection, as well as the number of outpatient lower respiratory infections caused by RSV. Safety profiles of each of the two compounds were excellent. Based on these data, motavizumab should eventually replace palivizumab in the prevention of RSV infection.
|
Authors | Michelle A Gill, Robert C Welliver |
Journal | Expert opinion on biological therapy
(Expert Opin Biol Ther)
Vol. 9
Issue 10
Pg. 1335-45
(Oct 2009)
ISSN: 1744-7682 [Electronic] England |
PMID | 19764889
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)
|
Chemical References |
- Antibodies, Monoclonal
- Antibodies, Monoclonal, Humanized
- RNA, Small Interfering
- Viral Vaccines
- motavizumab
|
Topics |
- Antibodies, Monoclonal
(pharmacokinetics, pharmacology, therapeutic use)
- Antibodies, Monoclonal, Humanized
- Clinical Trials as Topic
- Humans
- Infant
- RNA, Small Interfering
- Respiratory Syncytial Virus Infections
(prevention & control)
- Viral Vaccines
(administration & dosage, therapeutic use)
|